<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00406432</url>
  </required_header>
  <id_info>
    <org_study_id>PCR104075</org_study_id>
    <nct_id>NCT00406432</nct_id>
  </id_info>
  <brief_title>A Repeat Dose Pharmacokinetic Study Of Paroxetine CR Tablet In Healthy Chinese Subjects</brief_title>
  <official_title>A Steady-state Study to Assess the Pharmacokinetic Profile of Paroxetine After 14 Day Repeated Daily Dosing of the Controlled Release Paroxetine Tablet (25 mg) in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The study was designed to assess the steady-state pharmacokinetic profile of paroxetine after
      14 day repeated daily dosing of the controlled release tablet formulation (25 mg) in healthy
      Chinese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 9, 2006</start_date>
  <completion_date type="Actual">June 2, 2006</completion_date>
  <primary_completion_date type="Actual">June 2, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetic parameters</measure>
    <time_frame>Up to 21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety parameters(adverse events, lab test results,vital signs,electrocardiograph)</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Subjects receiving paroxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive single dose of paroxetine 25 milligrams controlled release formulation followed by wash-out period of 5 days. Subjects will receive multiple doses of paroxetine 25 milligrams for further 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine Controlled Release Tablet</intervention_name>
    <description>Eligible subjects will receive paroxetine controlled release tablet with dose of 25 milligrams.</description>
    <arm_group_label>Subjects receiving paroxetine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  19-45 years healthy Chinese subjects

          -  Body weight &gt; 50 kg

          -  BMI between 19-25

          -  serological negative for HIV, syphilis and hepatitis B and C

          -  no abnormalities in ECG

          -  Female with negative pregnancy and male has no plan to have a child during and 3
             months after the study.

        Exclusion criteria:

          -  History of chronic physical/mental disease, current disease and concomitant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/PCR104075?search=study&amp;study_ids=PCR104075#rs</url>
    <description>Results for study PCR104075 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2006</study_first_submitted>
  <study_first_submitted_qc>November 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRL029060/Paroxetine CR</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>repeat dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

